Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2013

View Archived Issues

Novel transgenic pig model of familial hypercholesterolemia

Vertex Pharmaceuticals synthesizes new protein kinase inhibitors

Argos Therapeutics enrolls first patients in phase III ADAPT study

Researchers at Amgen present novel TRPM8 antagonists

The Wisconsin Alumni Research Foundation patents novel vitamin D analogues

Celecoxib shows promise as adjunctive treatment in children with autism

AstraZeneca and Vanderbilt University enter collaboration

Galapagos delivers second candidate drug to Janssen Pharmaceutica

French grant awarded for development of epicutaneous pediatric RSV vaccine

Four NIH-supported studies focus on new treatments for Alzheimer's disease

CorMedix signs marketing agreement with MKM Co-Pharma for Neutrolin

Cytos updates on phase IIb allergic asthma study

Tysabri label update sought from the FDA and EMA

Detection of endometrial and ovarian cancers through DNA screening of Pap smears

European approval for Amyvid diagnostic radiopharmaceutical

FDA accepts for filing Tarceva sNDA

Unigene Laboratories designs polypeptides with anti-inflammatory activity

Isis Pharmaceuticals patents antisense modulators of FGFR-4

European approval for new 800-mg tablet of Prezista

Novel GnRH receptor antagonists emerge from Bayer R&D

New antidiabetic agents described in Metabolic Solutions Development patent

Zenobia Therapeutics develops novel LRRK2 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...